Axovant Sciences (AXON): Competitive Impact Should Be Minimal - Jefferies
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Axovant Sciences (NYSE: AXON) after Lundbeck announced that the PIII trial testing idalopirdine failed to meet its primary endpoint of reduction in ADAS-COG at week 24 when combined with donepezil. The analyst believes there are multiple key differences to AXON's intepirdine program and therefore does not expect it to be predictive of the MINDSET Phase III trial outcome. The analyst continues to be positive on AXON’s intepirdine in Alzheimer's.
No change to the price target of $31.
Shares of Axovant Sciences closed at $15.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex Pharma (VRTX): Recent Volatility Is a Buying Opportunity - Jefferies
- Oppenheimer Starts Axovant Sciences (AXON) at Outperform
- Guggenheim Reiterates Buy on United Natural Foods (UNFI) Following 1Q Report
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!